Teva to Report First Quarter 2016 Financial Results on May 9, 2016
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Guggenheim Remains Bullish Ahead of Teva Pharma's (TEVA) AGN Deal
April 18, 2016 11:38 AM EDTGuggenheim reiterated a Buy rating and $80.00 price target on Teva Pharma (NYSE: TEVA) ahead of a deal close and pipeline catalysts in 2016. The company's AGN generics deal is scheduled to close in June. Guggenheim Cut 2016 EPS estimates $0.35 to $5.17. The decreases in EPS estimates are... More
